All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Yale Researchers Develop Novel Antibody-RNA Therapy for Resistant Cancers

July 23rd 2025

More than 2 dozen Yale experts are collaborating on a therapy for the most defended tumors.

Inavolisib Plus Palbociclib/Fulvestrant Gains European Approval in PIK3CA-Mutant, HR+/HER2– Advanced Breast Cancer

July 23rd 2025

The European Commission has approved inavolisib plus palbociclib/fulvestrant in PIK3CA-mutant ER-positive, HER2-negative advanced breast cancer.

Subcutaneous Daratumumab Receives European Commission Approval in Smoldering Myeloma

July 23rd 2025

Subcutaneous daratumumab received EU approval for the treatment of patients with smoldering multiple myeloma at high risk of developing multiple myeloma.

European Commission Approves Ibrutinib in Treatment-Naive, Transplant-Eligible MCL

July 23rd 2025

Ibrutinib has received an expanded indication from the European Commission for the treatment of patients with newly diagnosed MCL eligible for transplant.

Global Disparities in Sarcoma Care Underscore Need for Timely Referral and Multidisciplinary Coordination

July 23rd 2025

R. Lor Randall, MD, FACS, discusses global disparities in sarcoma care during Sarcoma Awareness Month.

Analysis Links ctDNA Clearance to Improved Outcomes in Advanced Cervical Cancer

July 23rd 2025

Jyoti S. Mayadev, MD, discusses a ctDNA analysis from the CALLA study of chemoradiation with or without durvalumab in locally advanced cervical cancer.

Natural Language Processing Streamlines Clinical Encounter Note Collection in Indolent Systemic Mastocytosis

July 23rd 2025

Natural language processing models could help streamline processes within clinical settings.

Evolution of MDS Management Hinges on Standardized Disease Classification, Molecularly Informed Risk Stratification

July 22nd 2025

Hetty E. Carraway, MD, MBA, highlights the evolving molecular classification of MDS and novel agents in the therapeutic arsenal.

Talazoparib Plus Tazemetostat Is Safe, Generates Signs of Clinical Benefit in mCRPC

July 22nd 2025

The combination of talazoparib and tazemetostat was safe and led to PSA reductions in certain patients with metastatic castration-resistant prostate cancer.

Roswell Park Welcomes Eight New Physicians as Faculty Members

July 22nd 2025

Doctors join cancer center with expertise in surgical and medical oncology, pathology, dermatology, anesthesia.

FDA Grants Fast Track Designation to Next-Generation HER3-Directed ADC for EGFR+ Advanced NSCLC

July 22nd 2025

The FDA granted fast track designation to DB-1310 for patients with pretreated, advanced non–small cell lung cancer harboring select EGFR mutations.

SCIB1/iSCIB1+ Vaccines Plus Checkpoint Inhibition Generate Immune Responses in Advanced Melanoma

July 22nd 2025

Among patients with advanced melanoma and the target HLA type—representing 80% of the study population—treatment with iSCIB1+ yielded an ORR of 69%.

Accelerating US Oncology Drug Development Using Chinese First-in-Human Data

July 22nd 2025

Evan S. Wu, Md, PhD, concludes a three-part series highlighting the translatability of Chinese clinical data into US regulatory pathways.

FDA Issues CRL for RP1 Plus Nivolumab for Advanced Melanoma

July 22nd 2025

The FDA has issued a complete response letter for RP1 plus nivolumab for advanced melanoma after a PD-1 inhibitor–containing regimen.

Zidesamtinib Is Set to Overcome the Limitations of Current ROS1 TKIs in ROS1+ NSCLC

July 22nd 2025

Joshua K. Sabari, MD, discusses the design of the phase 1/2 ARROS-1 study, as well as key efficacy data with zidesamtinib in ROS1 fusion–positive NSCLC.

Oral Decitabine-Cedazuridine Is a Game Changer for MDS and CMML Treatment

July 22nd 2025

The oral formulation of decitabine-cedazuridine helps empower patients with MDS or CMML to maintain their quality of life from the comfort of their home.

Sequencing Considerations Are Important for T-Cell Redirection Therapies in Relapsed/Refractory Myeloma

July 21st 2025

Darren Pan, MD, highlighted key sequencing strategies for T-cell redirection therapy in relapsed/refractory multiple myeloma.

Interdisciplinary Grants Awarded for Cancer-Focused Engineering Projects

July 21st 2025

Innovative engineering teams at Huntsman Cancer Institute tackle cancer treatment challenges through collaborative grants.

EU Grants Conditional Approval of Mirdametinib for NF1-Associated Plexiform Neurofibromas

July 21st 2025

Mirdametinib received conditional EU approval for treating NF1-associated plexiform neurofibromas in patients 2 years of age and older.

European Commission Approves Obe-Cel for Adult R/R B-Cell Precursor Acute Lymphoblastic Leukemia

July 21st 2025

The European Commission approved obe-cel for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.